Insmed (INSM) Competitors $76.29 -1.71 (-2.19%) Closing price 04:00 PM EasternExtended Trading$76.98 +0.69 (+0.91%) As of 05:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends INSM vs. TAK, ALNY, TEVA, RPRX, BGNE, SMMT, UTHR, GMAB, VTRS, and ITCIShould you be buying Insmed stock or one of its competitors? The main competitors of Insmed include Takeda Pharmaceutical (TAK), Alnylam Pharmaceuticals (ALNY), Teva Pharmaceutical Industries (TEVA), Royalty Pharma (RPRX), BeiGene (BGNE), Summit Therapeutics (SMMT), United Therapeutics (UTHR), Genmab A/S (GMAB), Viatris (VTRS), and Intra-Cellular Therapies (ITCI). These companies are all part of the "pharmaceutical preparations" industry. Insmed vs. Takeda Pharmaceutical Alnylam Pharmaceuticals Teva Pharmaceutical Industries Royalty Pharma BeiGene Summit Therapeutics United Therapeutics Genmab A/S Viatris Intra-Cellular Therapies Takeda Pharmaceutical (NYSE:TAK) and Insmed (NASDAQ:INSM) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability, community ranking and analyst recommendations. Which has more risk & volatility, TAK or INSM? Takeda Pharmaceutical has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Comparatively, Insmed has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500. Does the MarketBeat Community favor TAK or INSM? Insmed received 442 more outperform votes than Takeda Pharmaceutical when rated by MarketBeat users. Likewise, 66.26% of users gave Insmed an outperform vote while only 56.82% of users gave Takeda Pharmaceutical an outperform vote. CompanyUnderperformOutperformTakeda PharmaceuticalOutperform Votes10056.82% Underperform Votes7643.18% InsmedOutperform Votes54266.26% Underperform Votes27633.74% Which has higher earnings and valuation, TAK or INSM? Takeda Pharmaceutical has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTakeda Pharmaceutical$28.20B1.55$994.06M$0.5823.66Insmed$305.21M46.53-$749.57M-$5.55-14.30 Do analysts recommend TAK or INSM? Insmed has a consensus price target of $83.67, indicating a potential upside of 5.39%. Given Insmed's stronger consensus rating and higher possible upside, analysts clearly believe Insmed is more favorable than Takeda Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Insmed 0 Sell rating(s) 0 Hold rating(s) 16 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to TAK or INSM? In the previous week, Takeda Pharmaceutical had 3 more articles in the media than Insmed. MarketBeat recorded 10 mentions for Takeda Pharmaceutical and 7 mentions for Insmed. Takeda Pharmaceutical's average media sentiment score of 0.56 beat Insmed's score of 0.46 indicating that Takeda Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Takeda Pharmaceutical 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Insmed 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders believe in TAK or INSM? 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by insiders. Comparatively, 4.6% of Insmed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is TAK or INSM more profitable? Takeda Pharmaceutical has a net margin of 6.49% compared to Insmed's net margin of -252.01%. Takeda Pharmaceutical's return on equity of 10.00% beat Insmed's return on equity.Company Net Margins Return on Equity Return on Assets Takeda Pharmaceutical6.49% 10.00% 4.78% Insmed -252.01%N/A -54.43% SummaryTakeda Pharmaceutical beats Insmed on 10 of the 18 factors compared between the two stocks. Get Insmed News Delivered to You Automatically Sign up to receive the latest news and ratings for INSM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INSM vs. The Competition Export to ExcelMetricInsmedPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.29B$6.62B$5.46B$9.26BDividend YieldN/A2.96%5.36%3.98%P/E Ratio-14.394.5958.7113.36Price / Sales46.53348.741,258.4982.95Price / CashN/A65.0944.3037.67Price / Book-34.225.215.054.66Net Income-$749.57M$154.35M$117.51M$224.41M7 Day Performance1.99%0.33%0.85%-1.00%1 Month Performance15.27%1.02%3.88%0.75%1 Year Performance174.03%7.67%25.80%18.03% Insmed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INSMInsmed2.7115 of 5 stars$76.29-2.2%$83.67+9.7%+176.9%$13.65B$305.21M-13.75373Short Interest ↑TAKTakeda Pharmaceutical4.2175 of 5 stars$13.35+2.7%N/A-9.6%$42.43B$28.20B22.9949,281Earnings ReportUpcoming EarningsShort Interest ↓News CoverageGap UpALNYAlnylam Pharmaceuticals4.0564 of 5 stars$275.67-1.1%$298.61+8.3%+51.4%$35.56B$1.83B-105.222,100Insider TradeAnalyst RevisionNews CoverageTEVATeva Pharmaceutical Industries3.624 of 5 stars$21.59-0.4%$22.63+4.8%+57.3%$24.47B$15.85B-25.4137,851Earnings ReportAnalyst ForecastOptions VolumeNews CoverageRPRXRoyalty Pharma4.8702 of 5 stars$31.65+1.9%$41.67+31.6%+10.0%$18.63B$2.36B16.3980BGNEBeiGene1.9803 of 5 starsN/A$253.69+∞N/A$18.03B$3.32B-22.429,000Analyst ForecastSMMTSummit Therapeutics2.9116 of 5 stars$23.06-2.9%$33.57+45.6%+474.0%$17.02B$700,000.00-82.44110UTHRUnited Therapeutics4.3175 of 5 stars$371.05+0.1%$378.36+2.0%+71.8%$16.56B$2.33B16.291,168Insider TradeShort Interest ↓Positive NewsGMABGenmab A/S3.8507 of 5 stars$21.06-0.4%$45.20+114.7%-29.8%$13.93B$2.39B20.442,204Short Interest ↑Analyst RevisionVTRSViatris3.3045 of 5 stars$11.42+1.9%$13.67+19.7%-4.6%$13.61B$15.43B-15.4138,000ITCIIntra-Cellular Therapies4.3277 of 5 stars$127.26-0.1%$102.15-19.7%+81.8%$13.49B$464.37M-146.27560Short Interest ↓ Related Companies and Tools Related Companies Takeda Pharmaceutical Competitors Alnylam Pharmaceuticals Competitors Teva Pharmaceutical Industries Competitors Royalty Pharma Competitors BeiGene Competitors Summit Therapeutics Competitors United Therapeutics Competitors Genmab A/S Competitors Viatris Competitors Intra-Cellular Therapies Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:INSM) was last updated on 1/30/2025 by MarketBeat.com Staff From Our PartnersPlease take this warning seriously...I’m here to issue a stark warning to you about an unexpected $2 trillion shock that could impact every trader ...Timothy Sykes | SponsoredIs Big Tech dead?China just threw a “$5.5 million” curveball called Deep Seek to Silicon Valley and the timing of it is no coin...Brownstone Research | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredDonald Trump is about to free crypto from its chains …On October 25th, Juan said Bitcoin would cross $100,000 before the inauguration. Now he thinks it could rea...Weiss Ratings | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredTrillion-Dollar Crypto PlayPotential $20-trillion opportunity? Put $500 into THIS AI Coin for 2025… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insmed Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Insmed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
